Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Armata Pharmaceuticals Inc Market Cap
From what 0 stock analysts predict, the share price for Armata Pharmaceuticals Inc (ARMP) might increase by 201.72% in the next year. This is based on a 12-month average estimation for ARMP. Price targets go from $7 to $7. The majority of stock analysts believe ARMP is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ARMP is a stock in Healthcare which has been forecasted to be worth $7 as an average. On the higher end, the forecast price is $7 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end ARMP is forecasted to be $7 by Joseph Pantginis from HC Wainwright & Co..
These are the latest 20 analyst ratings of ARMP.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 15, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Jul 11, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | May 8, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Maintains | Mar 22, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 14, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | May 12, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 17, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 7, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $7 | Maintains | Mar 22, 2021 |
H.C. Wainwright | Buy | Reiterates | May 15, 2020 | |
| Joseph Pantginis HC Wainwright & Co. | Buy | $5 | Reiterates | May 15, 2020 |
H.C. Wainwright | Buy | Reiterates | Mar 20, 2020 | |
| Joseph Pantginis HC Wainwright & Co. | Buy | $9 | Reiterates | Mar 20, 2020 |
Maxim Group | Buy | Initiates | Feb 6, 2020 | |
Ladenburg Thalmann | Buy | Initiates | Jun 19, 2019 |
When did it IPO
N/A
Staff Count
66
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Deborah L. Birx M.D.
Market Cap
$85.0M
In 2023, ARMP generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ARMP's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Armata Pharmaceuticals (ARMP) has received a Zacks Rank #2 (Buy) upgrade, indicating positive expectations for its earnings, which may boost the stock price in the near term.
Why It Matters - Armata Pharmaceuticals' Zacks Rank upgrade to #2 indicates positive earnings outlook, potentially boosting investor confidence and driving the stock price upward in the short term.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Armata Pharmaceuticals (NYSE: ARMP) announced Dr. Deborah Birx's involvement in the company, focusing on developing bacteriophage therapeutics for antibiotic-resistant infections.
Why It Matters - The announcement of Dr. Deborah Birx joining Armata Pharmaceuticals could enhance the company's credibility and attract investment, signaling potential growth in the biotechnology sector.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Armata Pharmaceuticals (NYSE: ARMP) will present at the 2024 Military Health System Research Symposium on August 26-29, focusing on bacteriophage therapeutics for antibiotic-resistant infections.
Why It Matters - Armata Pharmaceuticals' presentation at a prominent symposium highlights its innovative approach to antibiotic resistance, potentially boosting investor confidence in its market position and future growth.
Thu, 15 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Armata Pharmaceuticals appointed David House as Senior Vice President, Finance, effective August 16, 2024. Richard Rychlik remains Corporate Controller.
Why It Matters - The appointment of David House as SVP of Finance may enhance Armata Pharmaceuticals’ financial strategy and governance, potentially boosting investor confidence and company valuation.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Armata Pharmaceuticals reported financial results for Q2 2024 and announced completion of enrollment in its Phase 2 study for inhaled AP-PA02 targeting NCFB and Pseudomonas aeruginosa.
Why It Matters - Completion of enrollment in a key clinical study may signal progress towards potential product approval, impacting future revenue and stock performance for Armata Pharmaceuticals.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Armata Pharmaceuticals secured $5.25 million in non-dilutive funding from a Department of Defense grant to support clinical development of AP-SA02 for treating Staphylococcus aureus bacteremia.
Why It Matters - The additional $5.25 million grant enhances Armata Pharmaceuticals' funding for clinical trials, increasing its potential for successful drug development and attracting investor interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
